Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE, Mailstop D-26, Atlanta, GA, 30333, USA.
J Gen Intern Med. 2018 Jul;33(7):1060-1068. doi: 10.1007/s11606-018-4430-x. Epub 2018 Apr 20.
Detailed, nationally representative data describing high-risk populations and circumstances involved in antibiotic adverse events (AEs) can inform approaches to prevention.
Describe US burden, rates, and characteristics of emergency department (ED) visits by adults for antibiotic AEs.
Nationally representative, public health surveillance of adverse drug events (National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance [NEISS-CADES]) and a nationally projected database of dispensed prescriptions (QuintilesIMS), 2011-2015.
Antibiotic-treated adults (≥ 20 years) seeking ED care.
Estimated annual numbers and rates of ED visits for antibiotic AEs among outpatients treated with systemically administered antibiotics.
Based on 10,225 cases, US adults aged ≥ 20 years made an estimated 145,490 (95% confidence interval, 115,279-175,701) ED visits for antibiotic AEs each year in 2011-2015. Antibiotics were implicated in 13.7% (12.3-15.2%) of all estimated adult ED visits for adverse drug events. Most (56.6%; 54.8-58.4%) antibiotic AE visits involved adults aged < 50 years, and 71.8% (70.4-73.1%) involved females. Accounting for prescriptions dispensed from retail and long-term care pharmacies, adults aged 20-34 years had twice the estimated rate of ED visits for oral antibiotic AEs compared with those aged ≥ 65 years (9.7 [7.6-11.8] versus 4.6 [3.6-5.7] visits per 10,000 dispensed prescriptions, respectively). Allergic reactions accounted for three quarters (74.3%; 70.0-78.6%) of estimated ED visits for antibiotic AEs. The three most frequently implicated antibiotic classes in ED visits for antibiotic AEs were oral sulfonamides (23.2%; 20.6-25.8%), penicillins (20.8%; 19.3-22.4%), and quinolones (15.7%; 14.2-17.1%). Per-prescription rates declined with increasing age group.
Antibiotics are a common cause of ED visits by adults for adverse drug events and represent an important safety issue. Quantifying risks of AEs from specific antibiotics for specific patient populations, such as younger adults, provides additional information to help clinicians assess risks versus benefits when making the decision to prescribe or not prescribe an antibiotic. AE rates may also facilitate communication with patients about antibiotic risks.
详细的、具有全国代表性的数据描述了抗生素不良反应(AE)涉及的高危人群和情况,可为预防措施提供信息。
描述美国成年人因抗生素 AE 到急诊科(ED)就诊的负担、发生率和特征。
全国代表性的、公共卫生监测的药物不良事件(国家电子伤害监测系统-合作药物不良事件监测[NEISS-CADES])和全国预测的处方分发数据库(QuintilesIMS),2011-2015 年。
接受全身抗生素治疗的成年人(≥20 岁)寻求 ED 护理。
估计门诊接受系统给药抗生素治疗的成年人因抗生素 AE 而到 ED 就诊的年就诊人数和发生率。
基于 10225 例病例,2011-2015 年,美国≥20 岁成年人每年因抗生素 AE 到 ED 就诊的人数估计为 145490 例(95%置信区间,115279-175701)。抗生素在所有估计的成人药物不良事件的 ED 就诊中占 13.7%(12.3-15.2%)。大多数(56.6%;54.8-58.4%)抗生素 AE 就诊涉及年龄<50 岁的成年人,71.8%(70.4-73.1%)涉及女性。考虑到从零售和长期护理药房分发的处方,20-34 岁的成年人因口服抗生素 AE 而到 ED 就诊的估计比率是≥65 岁的成年人的两倍(分别为 9.7[7.6-11.8]和 4.6[3.6-5.7]次/每 10000 张处方)。过敏反应占抗生素 AE 估计 ED 就诊的四分之三(74.3%;70.0-78.6%)。在 ED 就诊的抗生素 AE 中,最常涉及的三种抗生素类别是口服磺胺类药物(23.2%;20.6-25.8%)、青霉素类(20.8%;19.3-22.4%)和喹诺酮类(15.7%;14.2-17.1%)。每处方的发生率随年龄组的增加而下降。
抗生素是成年人因药物不良事件到 ED 就诊的常见原因,是一个重要的安全问题。对特定人群(如年轻成年人)特定抗生素的 AE 风险进行量化,可为临床医生在决定是否开具抗生素时评估风险与获益提供额外信息。AE 发生率也有助于与患者就抗生素风险进行沟通。